Ignite Creation Date:
2024-07-17 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500273
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-06-26
Brief Title:
Consolidation of First-Line MRD Remission with Cema-cel in Patients with LBCL
Sponsor:
Allogene Therapeutics
Organization:
Allogene Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Large B-cell Lymphoma |
Keywords:
| Name | View |
|---|---|
| Diffuse large B-cell lymphoma | View |
| DLBCL | View |
| Primary mediastinal B-cell lymphoma | View |
| LBCL | View |
| High grade B-cell lymphoma | View |
| HGBCL | View |
| Double-hit lymphoma | View |
| High-risk lymphoma | View |
| Minimal Residual Disease | View |
| MRD | View |
| CAR T | View |
| Allogeneic CAR T | View |
| CD19 | View |
| cema-cel | View |
| cemacabtagene ansegedleucel | View |
| ALLO-647 | View |
| PMBCL | View |
| Consolidation | View |
| First-line | View |
| Front-line | View |
| Frontline | View |
| PhasED-Seq | View |
| CLARITY | View |
| Anti-CD52 | View |
| AlloCAR T | View |